What is Epithalon?
In short: Epithalon (Epitalon) is a synthetic tetrapeptide studied in cell cultures for telomerase activity. Its human evidence is the weakest covered here (older, single-group Russian work; no large controlled trial). Sold in vials and nasal bottles for research use only, it is not FDA-approved. A July 2026 FDA advisory vote (7–5–1) recommended it for compounding, changing nothing in law.
Epithalon — also spelled Epitalon, which is why search results for it are a mess — is a synthetic tetrapeptide studied in telomere and circadian-rhythm research. It is also, of the compounds covered on this site, the one where the gap between marketing language and published human evidence is widest. Both facts belong on the same page.
The basics
- Type: a synthetic tetrapeptide (alanine–glutamate–aspartate–glycine), modelled on epithalamin, a peptide preparation extracted from the pineal gland and studied by Russian researchers.
- Research focus: laboratory studies examine Epithalon in relation to telomerase activity in cell cultures, and in circadian/melatonin-pathway research.
- Formats sold: lyophilized vials (commonly 10 mg) and nasal-format bottles.
- Name note: "Epithalon" and "Epitalon" refer to the same compound; listings use both spellings.
What the evidence actually shows
This is the weakest human evidence base of any compound we cover, and independent evidence reviewers say so directly: the telomerase findings are from cell cultures, the human literature consists of older, single-group Russian work, and there is no convincing evidence of any human lifespan or health effect. Nothing has been tested in a large controlled human trial, and nothing has been reviewed by the FDA.
Epithalon remains a legitimate object of laboratory research — telomere biology is a serious field. What the evidence does not support is any seller presenting outcomes as expected, typical, or proven.
Regulatory status (October 2026)
Epithalon was the sixth compound in the FDA Pharmacy Compounding Advisory Committee's July 2026 session, recommended by a 7–5–1 vote. The usual facts apply, and they matter most precisely where the evidence is thinnest: the vote is advisory only, FDA staff opposed it, the FDA has not added Epithalon to the 503A Bulks List, and it cannot lawfully be compounded as of October 2026.
What Epithalon costs
Epithalon is one of the cheaper compounds in this market at trade level, yet retail listings carry the same wide vendor-to-vendor spread as everything else here. A cheap input plus a wide retail spread is exactly the combination where comparison shopping pays. Tracked ranges for all covered compounds are on the price-comparison page.
What to check before buying any research peptide
- Batch-specific COA from third-party testing (HPLC + mass spectrometry).
- Spelling check the label: Epithalon/Epitalon are the same compound; a listing that treats them as different products is a quality signal in itself.
- Claims check: the further a listing's language gets from "research use only," the more regulatory and quality risk it is signaling.
Epithalon is not in our planned store catalog. For compounds outside the planned catalog, our affiliate partner is Bench Grade Peptides (affiliate link; we may earn a commission).
Partner store: Bench Grade Peptides (affiliate link; we may earn a commission). Intended for laboratory research use only.
Related reading
- What is MOTS-c? — the other longevity-narrative compound from the July 2026 session.
- Research peptide price comparison — tracked prices across the catalogue.
- FAQ: what the advisory votes mean, and what they don't